Blueprint Medicines Corporation Stock News

Blueprint Medicines (BPMC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Deciphera's (DCPH) Qinlock, approved for treating advanced gastrointestinal stromal tumors, has seen strong uptake since its approval. However, heavy dependence on Qinlock for growth remains a woe.

Blueprint Medicines (NASDAQ:BPMC) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 6 1 5 1 1 L

Gainers GigaCloud Technology Inc (NASDAQ: GCT) shares jumped 206% to close at $48.01 on Friday on continued volatility following the company's IPO on Thursday. Aeglea BioTherapeutics, Inc. (NASDAQ:

HC Wainwright has cut the price target on Blueprint Medicines Corporation (NASDAQ: BPMC) from $100 to $80 and reiterated the Buy rating. The analyst attributes the stock's downward momentum to in

Blueprint Medicines (BPMC) posts top-line data from part 2 of the PIONEER study evaluating Ayvakit in patients with non-advanced systemic mastocytosis. Shares down.

Blueprint Medicines (BPMC) posts top-line data from part 2 of the PIONEER study evaluating Ayvakit in patients with non-advanced systemic mastocytosis. Shares down.

Gainers Blue Water Vaccines, Inc. (NASDAQ: BWV) shares climbed 199.6% to close at $7.64 on Wednesday after the company announced it plans to explore the potential development of a novel monkeypox vac

Earlier today, Blueprint Medicines Corporation (NASDAQ: BPMC) released the long-awaited pivotal PIONEER dataset in Indolent Systemic Mastocytosis (ISM).  The topline data indicates that the tria

Embark Technology, Inc. (NASDAQ: EMBK) fell 25.1% to $12.40. Embark Technology reported the completion of reverse stock split. Blueprint Medicines Corporation (NASDAQ: BPMC) fell 22.5% to $53.11 af

Gainers Blue Water Vaccines, Inc. (NASDAQ: BWV) shares jumped 79.5% to $4.57 after the company announced it plans to explore the potential development of a novel monkeypox vaccine using its norovirus

U.S. stocks traded lower this morning, with the Nasdaq composite dropping more than 150 points on Wednesday. The Dow traded down 0.52% to 33,973.33 while the NASDAQ fell 1.18% to 12,947.89. The S&P al

Blueprint unveiled the "long-awaited" results of its study in indolent systemic mastocytosis on Wednesday, and the biotech stock crashed. The post Blueprint Medicines Stock Hammered As 'Long-Awaited'

Shares of Blueprint Medicines Corp. BPMC, -2.00% tumbled 11.7% in premarket trading on Tuesday after the company said a Phase 2 clinical trial evaluating Ayvakit in patients with non-advanced systemic

Within the last quarter, Blueprint Medicines (NASDAQ:BPMC) has observed the following analyst ratings: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 3 1 5 1 1